NCT02970318 2026-02-06
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Acerta Pharma BV
Phase 3 Active not recruiting
Clinical Trials
11 trialsNCT04666038 2025-04-20
BRUIN CLL-321
Eli Lilly and Company
Phase 3 Active not recruiting
NCT02536300 2023-08-14
Dose Optimization Study of Idelalisib in Follicular Lymphoma
Gilead Sciences
Phase 3 Terminated
NCT01569295 2020-03-10
Tugela
Gilead Sciences
Phase 3 Completed
NCT01539291 2019-08-20
Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)
Gilead Sciences
Phase 3 Terminated
NCT01659021 2019-08-14
Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia
Gilead Sciences
Phase 3 Terminated
NCT01539512 2019-05-14
A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Gilead Sciences
Phase 3 Completed
NCT01980875 2018-11-19
Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia
Gilead Sciences
Phase 3 Terminated
NCT01980888 2018-11-19
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Gilead Sciences
Phase 3 Terminated
NCT01732913 2018-11-16
Yosemite
Gilead Sciences
Phase 3 Terminated
NCT01732926 2018-11-16
Bridalveil
Gilead Sciences
Phase 3 Terminated